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Abstract 
Candida spp. is the most prevalent species causing systemic fungal infections. The effect of antifungal agents were 
screened in vitro and their synergism effect were determined between hydroxychavicol (HC) in association with com‑
mercialized antifungal drugs—amphotericin B (AMB), and 5‑fluorocytosine (5‑FC) alone and in combination against 
five different oral Candida spp. in their planktonic states at different ratio (1:1 v/v; 1:2 v/v and 2:1 v/v). In vitro suscepti‑
bilities of Candida spp. to HC and commercialized antifungal agents were investigated by broth microdilution method 
as described by Clinical and Laboratory Standards Institute M38‑A2. The intensity of the interactions was evaluated by 
visual reading and spectrophotometric method in checkerboard microdiluton assay, and the nature of the interac‑
tions was assessed by fractional inhibitory concentration index. The minimum inhibitory concentration (MIC50) of 
HC, AMB and 5‑FC alone against five different planktonic oral Candida spp. ranged from 240 to 120, 8 to 15, and 2 to 
8 µg/mL respectively. Positive synergistic effect existed between HC and AMB at 1:1 ratio in all Candida spp. However, 
there was no synergy effect observed in the majority of Candida spp. for the combination of HC with 5‑FC. The data 
of combination between HC with AMB may be useful in the treatment of systemic infections caused by oral Candida 
spp. instead of the combination of HC with 5‑FC.
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Background
Invasive fungal infections, such as candidiasis, represent 
a public health problem of major importance. Since its 
discovery in 1839 by Langenbeck, the genus Candida has 
been shown to be the causative agent of many infections 
and represent a component of the normal flora in the oral 
cavity (Fridkin and Jarvis 1996). According to previous 
study, candidal adherence to mucosal surfaces is consid-
ered as a critical initial step in the pathogenesis of oral 
candidiasis (Bokor-Bratic 2008).
The high global incidence and prevalence of oral can-
didiasis may be attributed to an increasing usage of 
broad-spectrum antibiotics, cytotoxic, corticoster-
oids, and to a growing number of immuno-suppressed 
individuals as well as those with common endocrine 
disorders (such as diabetes mellitus) or severe nutri-
tional deficiencies (Johnson et  al. 2004). The increas-
ing incidence of fungal infections without a satisfactory 
response to the current antifungal therapy and the slow 
development of new agents with novel mechanisms of 
action have produced significant interest on associations 
between antifungal agents (Hemaiswaryaa et al. 2008).
HC is the major phenolic component, isolated from the 
aqueous extract of P. betle L., leafand has been reported 
to exhibit antibacterial activities against oral cavity path-
ogens (Sharma et  al. 2009) by inhibit the growth and 
disrupt the permeability barrier of microbial membrane 
structures. However, the report on its antifungal activity 
is lacking.
Polyenes such as AMB (isolated from Streptomycin 
spp.) bind to ergosterol and disrupt the major lipid com-
ponent of the fungal cell membrane. From 1950s until 
the discovery of the azoles, polyenes antifungal agents 
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represented the standard of therapy for systemic fungal 
infections (Sugar 1986). While, flucytosine (5-FC) is a 
synthetic antimycotic compound and possess no intrinsic 
antifungal capacity. It will be converted into 5-fluoroura-
cil (5-FU) once been taken up by susceptible fungal cells, 
and is further converted to metabolites that inhibit fun-
gal RNA and DNA synthesis (Vermes et al. 2000).
Some of the most effective antifungal drugs are too 
toxic for continuous use or can only be administered 
intravenously (Ghannoum and Rice 1999). The ideal anti-
fungal drug would be non-toxic, fungicidal, and amena-
ble to self-administration. Combination therapy is one 
approach that can be used to improve the efficacy of anti-
microbial therapy. Thus, the present study was carried 
out with the aim of investigating the combination of HC 
with AMB and 5-FC against planktonic of oral associated 
Candida spp.
Methods
Candida strains and growth condition
Five strains of Candida spp. used in this study were pur-
chased from The American Type Culture Collection 
(ATCC), USA. The species were C. albicans ATCC 14053, 
C. tropicalis ATCC 13803, C. parapsilosis ATCC 22019, 
C. lusitaniae ATCC 64125 and C. dubliniensis ATCC 
MYA-2975. Upon revival, each respective Candida strain 
was stored in 20 % v/v glycerol and kept in −70  °C. All 
strains were also subcultured monthly on Yeast Pep-
tone Dextrose (YPD) agar media (BD Difco, USA) and 
maintained weekly at 4  °C throughout the experimen-
tal period. Purity of the phenotypes was further con-
firmed by API Yeast Identification System (API 20C Aux, 
BioMerieux, France). Throughout the experiment period, 
the cultures were maintained on YPD agar up to a maxi-
mum of 2 weeks at 4 °C. Regular sub-culturing was car-
ried out every 2 weeks to maintain viability of the cells.
Preparation of the standard candida cell suspension, 
bioactive compound and antifungal agents
Each Candida strain was respectively cultured on Yeast 
Peptone Dextrose (YPD) agar media (BD Difco, USA) at 
37 °C for 24 h according to Harun et al. (2014). The tur-
bidity of the suspension was adjusted to an optical den-
sity (OD550nm) of 0.144 which is equivalent to 1  ×  106 
cells/mL. HC was isolated in the pure form from the 
chloroform extraction of the aqueous leaf extract of P. 
betle L., (Piperaceae) as described previously (Sharma 
et  al. 2009). AMB and 5-FC were obtained as standard 
liquid and powders purchased from Sigma Chemical Co. 
(St. Louis, MO).
A stock solution of 1000  µg/mL HC and 250  µg/mL 
AMB was prepared in 5 % DMSO and stored at 4 °C until 
used. A 5  % DMSO did not influence the growth and 
viability of fungi in a pilot study carried out prior to the 
experiment in our laboratory. A stock solution of 250 µg/
mL of 5-FC was prepared in sterile distilled water. AMB 
was also used in the study as the positive control.
Determination of MIC
The minimum inhibitory concentrations (MIC) of active 
compound and antifungal agentsalone against Candida 
spp. was determined according to the microdilution 
method of the CLSI M38-A2using 96-well microtiter 
plates with some modifications (Clinical and Laboratory 
Standards Institute 2008). This modification involved the 
usage of YPD instead of Sabaroud Dextrose Agar (SDA) 
or Potato Dextrose Agar (PDA) as describe in Harun 
et al. (2014). Concentration of ½ MIC was used through-
out the study as the research was focused in controlling 
the population of Candida spp. in the oral cavity rather 
than giving a complete killing effect, considering Can-
dida spp. as oral commensals. A broth microdilution 
method was recommended by CLSI as a general stand-
ard methodology for testing active compound or com-
mercialized antifungal agent. Thus, this method was 
employed to analysed the MIC of HC, AMB and 5-FC.
Each well contained the 10  µL of Candida spp. at a 
final concentration of 1.0 × 106 cells/mL, 100 µL of YPD 
broth, and 100  µL of HC, AMB and 5-FC. YPD broth 
without test agents was included as an agent-free con-
trol, and YPD broth was used as medium blank. All plates 
were incubated in an aerobic incubator at 37 °C for 24 h, 
after which the growth was determined spectrophoto-
metrically at 550  nm by means of a microplate reader 
(PowerWave 200, Bio-Tek Instruments, and Winooski, 
VT, USA). The data were reported as the median of at 
least 3 independent tests.
Assessment of HC and commercialized antifungal agents 
against Candida spp
Synergistic effects of HC to AMB and HC to 5-FC at a 
ratio of 1:1 v/v, 1:2 v/v and 2:1 v/v against five plank-
tonic of oral Candida spp. were quantitatively deter-
mined using the checkerboard microdilution method as 
described in previous study (Cuenca-Estrella 2004).
Briefly, 1000 µL HC, 250 µL AMB and 250 µL5-FC 
were used as initial concentration in this study. A 1:1 
ratio of either HC and AMB or HC and 5-FC was pre-
pared. Firstly, 50 µL of HC was added into well 1 of 96 
microtitre plate. Followed by an addition of 50  µL of 
either AMB. It was then serially diluted up to well 12. 
Inoculum of 1 × 106 cells/mL was added to each well and 
the plates were incubated at 37 °C for 24 h and read spec-
trophotometrically at 550 nm using a microplate reader 
(PowerWave 200, Bio-Tek Instruments, and Winooski, 
VT, USA). Negative control was prepared without the 
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addition of HC and AMB. Similar procedure was car-
ried out for 1:1 ratio of HC and 5-FC. The analysis was 
also performed with 1:2 and 2:1 ratio of HC:AMB and 
HC:5-FC.
The MIC combination was determined as the concen-
trations of antifungal drugs that resulted a 50  % reduc-
tion in absorbance compared to that of control. The MIC 
values of combined HC with AMB and 5-FC used to 
determine the fractional inhibitory concentration (FIC). 
The FIC index (∑FIC, the sum of individual FICs) was 
calculated using the formula: ∑FIC = MIC (Acomb)/MIC 
(Aalone) + MIC (Bcomb)/MI7C(Balone).
Two drugs or bioactive compounds are defined as hav-
ing synergistic effect, if the FIC indexes are ≤0.5, whereas 
they are said to have indifference when the FIC 0.5 but 
≤4, and antagonistic when FIC index was >4 (Cuenca-
Estrella 2004).
Results
MIC50 of HC, AMB and 5‑FC against oral Candida spp
The inhibitory activities of HC, AMB and 5-FC against a 
series of oral-associated Candida spp. were investigated 
(Table 1). Planktonic growth of Candida spp. was suscep-
tible to different antifungal drugs at varying concentra-
tions. The MIC50 range of HC against Candida spp. after 
24-h incubation was subsequently 240–120 µg/mL. It has 
been found that, C. parapsilosis and C. dubliniensis were 
the most susceptible to HC.
The MICs of individual AMB and 5-FC against the test 
strains of Candida species were lower than those of HC, 
ranging from 8 to 15 and 2 to 8 µg/mL, respectively.
AMB alone was active against C. tropicalis and C. dub-
liniensis at MIC of 4 µg/mL, C. albicans and C. parapsilo-
sis at MIC, of 8 µg/mL and C. lusitaniae at MIC of 15 µg/
mL.
5-FC alone was active against C. albicans, C. parapsilo-
sis and C. dubliniensis at 2 µg/mL of MIC concentration, 
while C. lusitaniae and C. tropicalis was slightly less sus-
ceptible to 5-FC at 4 and 8 µg/mL of MIC.
The effect of HC/AMB on the planktonic growth of Candida 
spp
Checkerboard analysis, has determined that the combi-
nation of HC and AMB having MIC of synergistic effect 
against five planktonic Candida spp. with ∑FIC index 
≥0.5. The FIC index for HC in combination with AMB 
was calculated as shown in Tables 1, 2 and 3. The com-
bination HC/AMB at 1:1 ratio yielded synergism inter-
action against all five Candida species, while at 1:2 and 
2:1 ratio of combination, C. tropicalis and C. lusitaniae 
showed indifferent effect.
At 1:1, 1:2 and 2:1 ratio of HC/AMB against C. albi-
cans, the MIC of HC were decreased up to 120- to 
60-fold, while MIC of AMB were decreased about 8- to 
16-fold. As shown in Table 1, strong synergistic effect has 
been demonstrated at 1:1 and 2:1 ratio with the FIC index 
of 0.07.
Against C. parapsilosis, strong synergistic effect has 
been observed at 2:1 ratio of HC/AMB with the FIC 
index of 0.08, where the MIC combination was mark-
edly decreased (60- to 4-fold respectively). However, at 
1:1 and 1:2 ratios, the synergism effect was also observed 
with the FIC index of 0.16, which is slightly higher than 
those observed in 2:1 ratio.
As illustrated in Table  1, a synergistic effect was 
observed against C. tropicalis (FICI, 0.27) at 1:1 ratio, 
however showed indifferent effect in 2:1 (FICI, 0.53) and 
1:2(FICI, 1.06) ratios. MIC of HC/AMB in 1:1 ratio has 
shown decreased of about 60-fold and 8-fold respectively 
(Table 1).
Against C. dubliniensis, the MIC of HC in association 
with AMB at 1:1 ratio decreased about 60:8-fold (FICI, 
0.26) where synergism was observed. Differently, a syn-
ergism was also found at 1:2 and 2:1 ratio with FIC index 
Table 1 Susceptibilities of standard Candida spp. to HC alone and in combination with AMB and 5-FC (1:1) ratio
MIC and FICI values are shown as a mean of three independent experiments
ANT antagonism, IND indifference, SYN synergy, INT interpretation
a The MIC end point is based on the lowest drug concentration producing a decrease of 50 % inhibition of fungal growth compared to untreated
b MIC of HC when in combination with AMB
c MIC of HC when in combination with 5‑FC
Species MIC (µg/mL) alonea MIC (µg/mL) combination (1:1) ratioa
HC Amp B 5‑FC HCb Amp B HC + Amp B FICI INT HCc 5‑FC HC + 5‑FC FICI INT
C. albicans 240 8 2 2 0.5 0.07 SYN 8 2 1.03 IND
C. parapsilosis 120 8 2 4 1 0.16 SYN 15 4 2.04 IND
C. tropicalis 240 4 8 4 1 0.27 SYN 30 8 1.13 IND
C. dubliniensis 120 4 2 2 0.5 0.26 SYN 15 4 2.13 IND
C. lusitaniae 240 15 4 8 2 0.17 SYN 8 2 0.53 IND
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of 0.29 and 0.28 where the MIC were decreased about 
30:4-fold.
Against C. lusitaniae, it was found that a combination of 
HC and AMB exhibited strong synergism in 1:1 and 2:1 ratios 
with the FICI index of 0.17. The MIC of HC and AMB giving 
a synergistic effect was found to be 30 and 8- fold lower than 
the MIC alone respectively. In comparison, the lowest activity 
was displayed at 1:2 with the FIC index of 0.67.
The effect of HC/5‑FC on the planktonic growth of Candida 
spp
The MIC of the combination of HC/5-FC as well as the 
MICs of the single drug tested at the ratio of 1:1, 1:2 and 
2:1, are given in Tables 1, 2 and 3. The FICI values ranged 
from 0.53 to 2.13 for the combination at 1:1 ratio, from 
1.06 to 2.06 for 1:2 ratio and from 1.06 to >4 for 2:1 ratio.
As shown in Table  1, only C. lusitaniae of the com-
bination of HC/5-FC in 1:1 ratio after 24-h incubation 
had partial synergistic properties with FIC index of 0.53. 
Indifferent interactions were observed in C. albicans, C. 
parapsilosis, C. tropicalis and C. dubliniensis with FIC 
index of 2.25 and 1.06 respectively.
All of Candida spp. showed indifferent reaction at 1:2. 
However, antagonism has been observed for C. albi-
cans and C. dubliniensis with FIC index >4 at 2:1 ratio. 
The MIC of 5-FC against C. albicans and C. dublinien-
sis increased up to fourfold. Our data showed 5-FC alone 
demonstrated greater effectiveness than in combination 
with HC against all Candida spp.
Discussion
Treating Candida infections with monotherapy is 
becoming more difficult, a major problem being the 
emerging drug resistance during treatment with various 
conventional antifungal agents. The mechanisms of anti-
fungal resistance are categorized as primary or secondary 
and are related to intrinsic or acquired characteristics of 
the fungal pathogen, including interference with the anti-
fungal mechanism of the respective drug or the decrease 
in target drug levels (Akins and Sobel 2009). Hence, 
there is a need to search or develop new formulation by 
using combinations as alternate and effective antifungal 
agents that have few or no side effects. The selection of 
the ATCC reference strains C. albicans, C. parapsilosis, 
Table 2 Susceptibilities of standard Candida spp. to HC alone and in combination with AMB and 5-FC (1:2) ratio
MIC and FICI values are shown as a mean of three independent experiments
ANT antagonism, IND indifference, SYN synergy, INT interpretation
a The MIC end point is based on the lowest drug concentration producing a decrease of 50 % inhibition of fungal growth compared to untreated
b MIC of HC when in combination with AMB
c MIC of HC when in combination with 5‑FC
Species MIC (µg/mL) alonea MIC (µg/mL) combination (1:2) ratioa
HC Amp B 5‑FC HCb Amp B HC + Amp B FICI INT HCc 5‑FC HC + 5‑FC FICI INT
C. albicans 240 8 2 4 1 0.14 SYN 15 4 2.06 IND
C. parapsilosis 120 8 2 4 1 0.16 SYN 8 2 1.06 IND
C. tropicalis 240 4 8 15 4 1.06 IND 30 8 1.13 IND
C. dubliniensis 120 4 2 4 1 0.29 SYN 8 2 1.06 IND
C. lusitaniae 240 15 4 30 8 0.67 IND 15 4 1.06 IND
Table 3 Susceptibilities of standard Candida spp. to HC alone and in combination with AMB and 5-FC (2:1) ratio
MIC and FICI values are shown as a mean of three independent experiments
ANT antagonism, IND indifference, SYN synergy, INT interpretation
a The MIC end point is based on the lowest drug concentration producing a decrease of 50 % inhibition of fungal growth compared to untreated
b MIC of HC when in combination with AMB
c MIC of HC when in combination with 5‑FC
Species MIC (µg/mL) alonea MIC(µg/mL) combination (2:1) ratioa
HC Amp B 5‑FC HCb Amp B HC + Amp B FICI INT HCc 5‑FC HC + 5‑FC FICI INT
C. albicans 240 8 2 2 0.5 0.07 SYN 30 8 >4 ANT
C. parapsilosis 120 8 2 2 0.5 0.08 SYN 15 4 2.25 IND
C. tropicalis 240 4 8 8 2 0.53 IND 30 8 1.12 IND
C. dubliniensis 120 4 2 4 1 0.28 SYN 30 8 >4 ANT
C. lusitaniae 240 15 4 8 2 0.17 SYN 15 4 1.06 IND
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C. tropicalis, C. dubliniensis, and C. lusitaniae was based 
on various reports of the prevalence of Candida species 
in the oral cavity (Harun et al. 2014). Although the refer-
ence strains were isolated originally from blood, similar 
strains have also been reported to be present in the oral 
cavity (Harun et al. 2014).
In recent years, the use of natural compound in com-
bination with conventional antifungal agents to achieve 
drug synergy has attracted much attention. Natural com-
pound with high effectiveness and fewer side effects are 
desirable as substitutes for chemical treatments which 
have various adverse effects. Piper betle L., (Piperaceae) 
has been extensively used in traditional herbal remedies 
in India, China, Taiwan, Thailand and many other coun-
tries. It is reported to possess various pharmacological 
activities such as antimicrobial, antioxidant; antimuta-
genic; anticarcinogenic; anti-inflammatory and etc. 
(Hemaiswaryaa et  al. 2008). Piper betle was reported 
as good anticandidal agent since it contains bioactive 
components such as 4-chromanol (Kawsud et  al. 2014), 
allylpyrocatechol (Dwivedi and Tripathi 2014), hydroxy-
chavicol (Dwivedi and Tripathi 2014) and others.
HC has been reported to have antifungal activity. 
Although it is a useful natural compound for treating 
fungal infections, its high MIC prevents its effective use 
in clinical study. Therefore, it will be more effective to use 
HC in combination with conventional antifungal agents 
rather than used alone. To our knowledge, the in  vitro 
phenomenon of synergism of HC with AMB and 5-FC 
against Candida spp. is reported here for the first time.
There are many models for experimental designs 
to measure such combination effects. One of the best 
known and very simple forms of such tests is the ‘cheq-
uerboard’ experiment in which a two dimensional array 
of serial concentrations of test compounds is used as the 
basis for calculation of a fractional inhibitory concentra-
tion index (FICI) (William et  al. 2003). Applying these 
ideas to in  vivo and clinical investigations of combina-
tion antifungal therapy is difficult, and no standards for 
interpretation of these data have been recommended. 
Analysis and comparison of results across in  vivo and 
clinical studies requires careful consideration of the 
nature of pathogen, host, host immune status, study 
design, and study endpoints (Melissa et  al. 2004). The 
effects observed in these models will not precisely apply 
to all aspects of the clinical. However, in  vitro testing 
might suggest an effective antifungal at which the dose 
needed to achieve the desired effect. They also represent 
the best-controlled data we have and, upon review, they 
help us gain a better understanding of how these drugs 
might behave when used together. They also represent 
the best-controlled data we have and, upon review, they 
help us gain a better understanding of how these drugs 
might behave when used together. Thus, the only way to 
resolve some of these issues is to use the available in vitro 
and in vivo data to drive the design of carefully selected 
clinical studies of combination therapy in patients.
Combination between HC and AMB at 1:1, 1:2 and 
2:1 ratio has resulted synergistic against most of spe-
cies tested. While combination of HC with 5-FC at 1:1, 
1:2 and 2:1 ratio has resulted indifferent and antagonis-
tic interaction. Combinationat 1:1 ratio between HC with 
AMB considered as a good antifungal combination since 
it showed synergistic effect at lowest ratio used in this 
study against Candida spp.
In the search for the mechanism of synergism between 
HC with AMB, their individual antifungal modes of 
action need to be considered. From previous study, they 
reported that, HC alters the cell membrane structure, 
resulting in the disruption of the permeability barrier of 
microbial membrane structure (Nalina and Rahim 2007). 
While, polyenes antifungal are able to bind to ergosterol 
which is the main sterol in the fungal cell membrane. 
Enzymes in the ergosterol pathways are the targets of 
many antifungal agents. AMB binds with ergosterol, a 
component of fungal cell membranes, forming pores that 
cause rapid leakage of monovalent ions and subsequent 
fungal cell death (Mesa-Arango et al. 2012).
More importantly, our results showed that addition of 
HC to AMB could possibly enable reduced dosages of 
both agents and thus potentially reduced drug-associated 
toxicities which are frequently observed at the high dos-
ages of using AMB alone (Van’t Hof et al. 2000). Although 
the exact mechanism of interaction between HC and 
AMB is not known, it is possible that the simultaneous 
inhibition of different fungal cell targets occur. Combina-
tion of HC/AMB appears to involve the disruption of cell 
membrane structure that cause rapid leakage of monova-
lent ions allows the passage of one or both agents. Thus, 
the synergism effect was observed in this combination.
5-FC resistant strains of Candida being clinically sig-
nificant, thus there is a need for the development of new 
therapeutic agents especially in combination studies 
(Bondaryk et al. 2013). The results of these study provide 
evidence of antagonism effect between the combination 
of HC with 5-FC, and suggested that these agents should 
not be co-administered. A detailed mechanism explana-
tion why the combination of HC and 5-FC antagonistic is 
unknown. It also can be suggested that it might be related 
to the disruption and changes in fungal cell membrane 
function due to the effect of HC at first place. According 
to Patel (1998), 5-FC is used in combination with other 
antifungal, such as AMB rather than used as monother-
apy due to the increasing of drug resistance in combating 
fungal pathogens. In  vitro data regarding the combina-
tion of both drugs against Candida species are numerous 
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and somewhat contradictory showing antagonistic (Van-
deputte et al. 2012).
Conclusion
In conclusion, HC has antifungal activity but a very high 
MIC value against oral Candida spp. However, the com-
bination of HC with AMB exhibited a synergistic activity 
against all tested Candida species. Whereas, in combi-
nation with 5-FC exhibited indifference and antagonism 
activity. Therefore, the combination of HC/AMB effec-
tive at treating fungal infections and might be promis-
ing for future research into the pharmacological aspect. 
However, in vivo testing needs to be performed to sup-
port these findings.
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